Regina Herbst
About
Regina Herbst is a scholar working on Hematology, Genetics and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Regina Herbst has authored 28 papers receiving a total of 585 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 7 papers in Genetics and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Regina Herbst's work include Acute Myeloid Leukemia Research (14 papers), Hematopoietic Stem Cell Transplantation (7 papers) and Multiple Myeloma Research and Treatments (5 papers). Regina Herbst is often cited by papers focused on Acute Myeloid Leukemia Research (14 papers), Hematopoietic Stem Cell Transplantation (7 papers) and Multiple Myeloma Research and Treatments (5 papers). Regina Herbst collaborates with scholars based in Germany, United States and Slovakia. Regina Herbst's co-authors include Gerhard Ehninger, Gottfried Dölken, Mathias Hänel, Markus Schaich, M. Thalheimer, Martin Kaufmann, Anne F. Klenner, Anthony D. Ho, Kerstin Schaefer‐Eckart and Lothar Leimer and has published in prestigious journals such as The Lancet, Blood and Neurology.
In The Last Decade
Regina Herbst
26 papers receiving 573 citations
Peers
Regina Herbst
Krzysztof Chojnowski Poland
Ramin Tehranchi United States
M. Kloss Germany
Lone Hvitfeldt Poulsen Denmark
AB Federici Italy
Paul Kaywin United States
Francesca Palombi Italy
Silvia Vettore Italy
Cristina Falcó Spain
D. J. Meiklejohn United Kingdom
Citations per year, relative to Regina Herbst Regina Herbst (= 1×)
peers
Krzysztof Chojnowski
Countries citing papers authored by Regina Herbst
Since
Specialization
Citations
This map shows the geographic impact of Regina Herbst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Regina Herbst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Regina Herbst more than expected).
Fields of papers citing papers by Regina Herbst
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Regina Herbst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Regina Herbst. The network helps show where Regina Herbst may publish in the future.
Co-authorship network of co-authors of Regina Herbst
This figure shows the co-authorship network connecting the top 25 collaborators of Regina Herbst. A scholar is included among the top collaborators of Regina Herbst based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Regina Herbst. Regina Herbst is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Herbst, Regina, Annette Hänel, Anke Morgner, et al.. (2024). Challenges in the treatment of soft-tissue plasmacytoma: a retrospective analysis of 120 patients with extramedullary multiple myeloma. Journal of Cancer Research and Clinical Oncology. 150(10). 482–482.
2.
Hänel, Mathias, Georg Maschmeyer, Regina Herbst, et al.. (2018). Outcome at Two Years after a Response-Adapted Approach with Azacitidine and Intensive Chemotherapy in Patients > 60 Years with Newly Diagnosed AML Treated within the DRKS00004519 Trial of the East German Study Group (OSHO). Blood. 132(Supplement 1). 83–83.
3.
Herold, Sylvia, Katja Sockel, Cyrus Sayehli, et al.. (2017). Evolution of NPM1-negative therapy-related myelodysplastic syndromes following curative treatment of NPM1-mutant AML. Leukemia. 31(10). 2247–2251.
4.
Wermke, Martin, Claudia Schuster, Florian Nolte, et al.. (2016). Mammalian‐target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS ) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D‐MDS). British Journal of Haematology. 175(5). 917–924.
5.
Thiel, Andreas, Johannes Schetelig, Wolfram Pönisch, et al.. (2015). Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML—long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL). Annals of Oncology. 26(7). 1434–1440.
6.
Al‐Ali, Haifa Kathrin, Nadja Jaekel, Rainer Krahl, et al.. (2015). Response-Adapted Sequential Azacitidine and Induction Chemotherapy in Patients > 60 Years Old with Newly Diagnosed AML Eligible for Chemotherapy (RAS-AZIC): First Data of the Interim Analysis of the DRKS00004519 Study of the East German Study Group (OSHO). Blood. 126(23). 1346–1346.
7.
Wandt, Hannes, Kerstin Schaefer‐Eckart, Knut Wendelin, et al.. (2012). Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. The Lancet. 380(9850). 1309–1316.
8.
Kiefer, Thomas, Carsten Hirt, Frank Schüler, et al.. (2011). Long-term follow-up of high-dose chemotherapy with autologous stem-cell transplantation and response-adapted whole-brain radiotherapy for newly diagnosed primary CNS lymphoma: results of the multicenter Ostdeutsche Studiengruppe Hämatologie und Onkologie OSHO-53 phase II study. Annals of Oncology. 23(7). 1809–1812.
9.
Parmentier, Stefani, Martin Bornhäuser, Christian Thiede, et al.. (2011). No Benefit of Combining Additional Compounds with Standard High Dose Cytarabine Consolidation: Results of the Prospective Randomized AML2003 Study. Blood. 118(21). 255–255.
10.
Krämer, Michael, Mathias Hänel, Regina Herbst, et al.. (2010). Induction Treatment In Elderly Patients with Acute Myeloid Leukemia (AML): Randomized Comparison of Intermediate-Dose Cytarabine Plus Mitoxantrone (IMA) Versus Standard-Dose Cytarabine Plus Daunorubicin (DA) In 492 AML Patients >60 Years – Results From the SAL 60plus Trial. Blood. 116(21). 334–334.
11.
Giagounidis, Aristoteles, Gudrun Göhring, Sabine Haase, et al.. (2009). Discontinuation of Lenalidomide in Patients with Transfusion-Dependent Low- and Intermediate-1 Risk Myelodysplastic Syndromes with Del(5q): Sustained Remissions, but Not Cure.. Blood. 114(22). 3807–3807.
12.
Montemurro, Michael, Thomas Kiefer, Frank Schüler, et al.. (2006). Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hämato-Onkologie OSHO-53 phase II study. Annals of Oncology. 18(4). 665–671.
13.
Bornhäuser, Martin, Mathias Hänel, Markus Schaich, et al.. (2005). Graft clonogenicity and intensity of pre-treatment: factors affecting outcome of autologous peripheral hematopoietic cell transplantation in patients with acute myeloid leukemia in first remission. Bone Marrow Transplantation. 36(12). 1083–1088.
14.
West, Howard, Robert O. Kerr, Diane Prager, et al.. (2005). P-497 ZD6474 in combination with carboplatin and paclitaxel as first-line treatment in patients with NSCLC: Results of the run-in phase of a two-part randomized Phase II study. Lung Cancer. 49. S247–S247.
15.
Hänel, Mathias, Annette Hänel, Regina Herbst, et al.. (2001). Mito-FLAG as Salvage Therapy for Relapsed and Refractory Acute Myeloid Leukemia. Oncology Research and Treatment. 24(4). 356–360.
16.
Hänel, Mathias, Nicolaus Kröger, Frank Kroschinsky, et al.. (2001). Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma. Journal of Cancer Research and Clinical Oncology. 127(6). 387–395.
17.
Strauss, Gary M., Thomas J. Lynch, Alby Elias, et al.. (1997). Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis.. PubMed. 24(4 Suppl 12). S12–73.
18.
Wen, Patrick Y., E. Alyea, David Simon, et al.. (1997). Guillain-Barre syndrome following allogeneic bone marrow transplantation. Neurology. 49(6). 1711–1714.
19.
Herbst, Regina. (1967). �ber den Einflu� der adaptierten Milch auf die Fr�hgeborenen-Aufzucht. European Journal of Pediatrics. 98(3). 208–215.
20.
Herbst, Regina, et al.. (1966). Das transitorische Diabetes mellitus-Syndrom des Neugeborenen, ein Krankheitsbild sui generis. European Journal of Pediatrics. 95(4). 324–347.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Krzysztof Chojnowski Breakdown of academic impact, for papers by Ramin Tehranchi Breakdown of academic impact, for papers by M. Kloss Breakdown of academic impact, for papers by Lone Hvitfeldt Poulsen Breakdown of academic impact, for papers by AB Federici Breakdown of academic impact, for papers by Paul Kaywin Breakdown of academic impact, for papers by Francesca Palombi Breakdown of academic impact, for papers by Silvia Vettore Breakdown of academic impact, for papers by Cristina Falcó Breakdown of academic impact, for papers by D. J. Meiklejohn